Cortechs.ai, a global leader in AI-driven neuroimaging solutions, today announced a strategic collaboration with the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) aimed at elevating care quality for individuals living with Alzheimer’s disease. This partnership integrates Cortechs.ai’s advanced NeuroQuant® for ARIA imaging platform with ALZ-NET’s comprehensive real-world data network to support clinical decision-making, enhance care delivery, and influence future treatment guidelines. As part of this initiative, ALZ-NET clinical sites will receive discounted access to NeuroQuant® for ARIA, enabling broad adoption across diverse clinical environments.
AI-Driven Imaging Innovation for Alzheimer’s Patient Safety
NeuroQuant® for ARIA provides precise segmentation, quantification, and longitudinal tracking of FLAIR and T2GRE/SWI lesions, crucial for monitoring amyloid-related imaging abnormalities (ARIA-E and ARIA-H) in patients undergoing anti-amyloid therapies. Validated on both 2D and 3D FLAIR sequences, it supports a wide range of imaging protocols. Notably, NeuroQuant® for ARIA is the only clinically validated solution capable of detecting cerebral microbleeds and superficial siderosis on T2GRE and SWI scans, alongside quantifying cerebral edema through FLAIR lesion tracking.
Expert Endorsements and Real-World Impact
Dr. Ana Franceschi, renowned dementia imaging and molecular neuroimaging expert, and member of Cortechs.ai’s Medical Advisory Board as well as ALZ-NET’s Imaging Work Group, highlights the collaboration’s significance:
“Combining advanced neuroimaging analytics with real-world data is a critical step in optimizing safety and monitoring for Alzheimer’s patients receiving anti-amyloid therapies. This collaboration holds great promise for clinicians and patients alike.”
Harnessing Real-World Data to Drive Alzheimer’s Treatment Insights
ALZ-NET, sponsored by the Alzheimer’s Association® and operated by the American College of Radiology® (ACR®), is a voluntary multi-site network that collects clinical and imaging data from patients treated with FDA-approved Alzheimer’s therapies. By pooling longitudinal, real-world data, ALZ-NET aims to generate evidence-based insights into the long-term safety and efficacy of these treatments.
Kyle Frye, CEO of Cortechs.ai, stated:
“Our collaboration with ALZ-NET reflects a shared commitment to leveraging data and technology to improve care for people with dementia. NeuroQuant® for ARIA equips clinicians with vital tools for smarter, safer decisions, and connecting with ALZ-NET’s data network allows us to collectively advance Alzheimer’s treatment practices.
This collaboration sets a new benchmark for AI-powered neuroimaging combined with real-world data to improve outcomes for Alzheimer’s patients worldwide.
